Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar (Q46041746)

From Wikidata

Jump to navigation Jump to search

scientific article published on 3 October 2013

Language	Label	Description	Also known as
English	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar	scientific article published on 3 October 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

1 reference

based on heuristic

inferred from title

5

object named as

Jos H Beijnen

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

author name string

Seng Chuan Tang

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

Luan N Nguyen

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

Rolf W Sparidans

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

Els Wagenaar

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

Alfred H Schinkel

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

language of work or name

0 references

publication date

3 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

134

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

1484-1494

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

Global patterns of cancer incidence and mortality rates and trends

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Oncogenic mutations of ALK kinase in neuroblastoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

A mouse model for EML4-ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec® ) across the mouse blood-brain barrier

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Brain distribution and bioavailability of elacridar after different routes of administration in the mouse

1 reference

https://api.crossref.org/works/10.1002%2FIJC.28475

21 January 2018

Identifiers

10.1002/IJC.28475

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/24037730

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46041746&oldid=2089309229"